COPD: Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"The Associations Between Socioeconomic Deprivation, Social Isolation and Sedentary Time in COPD: A UK Biobank Study.","authors":"Stefanie Harding, Alan Richardson, Angela Glynn, Luke Middleton, Luke Hodgson","doi":"10.1080/15412555.2026.2713066","DOIUrl":"10.1080/15412555.2026.2713066","url":null,"abstract":"<p><strong>Background: </strong>People with COPD are more likely to be sedentary, a behaviour associated with reduced life expectancy. COPD is also associated with social isolation and socioeconomic deprivation. Therefore, this study aimed to examine the relationship between these determinants and sedentary time.</p><p><strong>Methods: </strong>This study analysed 23,559 UK Biobank participants with COPD (recruited 2006-2010), with a follow-up accelerometer assessment (2013-2015). Primary analyses were performed on accelerometer participants (<i>n</i> = 1,558) with complete covariate and accelerometer data. Associations between sedentary time, social isolation, and deprivation were explored using multivariable linear regression, stratified by COPD severity (GOLD stages).</p><p><strong>Results: </strong>Sedentary time rose stepwise with disease severity (<i>p</i> < 0.001); with GOLD 4 individuals spending 19% more of their day sedentary than GOLD 1. Social isolation interacted with severity (<i>p</i> = 0.033), predicting an extra 1.5 h of daily sedentary time in GOLD 3-4 (95% CI, 0.49-2.47; <i>p</i> = 0.004). Deprivation had the greatest impact on sedentary time in mild disease.</p><p><strong>Conclusions: </strong>This large observational study suggests sedentary behaviour is associated with social isolation in severe COPD and socioeconomic deprivation in mild disease severity. This highlights the need to consider individual social and environmental factors alongside a clinical focus to reduce sedentary behaviour.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2713066"},"PeriodicalIF":2.8,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COPD and Dysphagia, a 2-Year Follow-up of the Prospective TIE-Cohort Study.","authors":"Margareta Gonzalez Lindh, Kristina Bröms, Andreas Palm, Karin Lisspers, Björn Ställberg, Christer Janson, Juan Wang, Jens Ellingsen, Marieann Högman, Andrei Malinovschi","doi":"10.1080/15412555.2026.2710155","DOIUrl":"https://doi.org/10.1080/15412555.2026.2710155","url":null,"abstract":"<p><strong>Background: </strong>Swallowing dysfunction (dysphagia) is increasingly recognised in chronic obstructive pulmonary disease (COPD) and has been associated with aspiration, exacerbations, and impaired health status. However, longitudinal data on dysphagia in COPD are limited.</p><p><strong>Aim: </strong>To investigate the 2-year stability of self-perceived dysphagia in a COPD cohort and to identify factors associated with persistent dysphagia.</p><p><strong>Methods: </strong>This prospective cohort study included 438 patients with spirometry-confirmed COPD from the Swedish Tools for Identifying Exacerbations (TIE) study. Self-reported swallowing symptoms were assessed at baseline and at 2-year follow-up using three questions. Dysphagia was defined as the presence of at least one symptom. Clinical assessments included lung function, dyspnoea (mMRC), health status (CAT), physical performance, body mass index (BMI), and exacerbation history. Dysphagia trajectories over time were analysed.</p><p><strong>Results: </strong>The prevalence of patient-reported dysphagia remained stable over the 2-year period (32% at baseline vs. 33% at follow-up). Four dysphagia trajectories were identified: no dysphagia (59%), incident dysphagia (8%), remission (8%), and persistent dysphagia (25%). Participants with dysphagia at follow-up had higher dyspnoea and CAT scores, poorer physical performance, higher BMI, and more frequent exacerbations. Persistent dysphagia was associated with a consistently higher symptom burden and poorer functional outcomes over time. In multivariate analysis, CAT ≥10 remained independently associated with dysphagia.</p><p><strong>Conclusion: </strong>Self-perceived dysphagia affects approximately one-third of individuals with COPD and remains stable over two years. Persistent dysphagia may identifiy a more symptomatic COPD phenotype and warrants clinical attention. These findings support the inclusion of simple swallowing screening in routine COPD follow-up.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2710155"},"PeriodicalIF":2.8,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Assessment of Smokers with Persistent Dyspnoea but Unremarkable Spirometry: The Added Value of Diffusing Capacity for Carbon Monoxide.","authors":"Matthew D James, Sandra G Vincent, Amany F Elbehairy, Devin B Phillips, J Alberto Neder, Satvir S Dhillon, Christopher J Ryerson, Wan Tan, Jordan A Guenette, Michael K Stickland, Denis E O'Donnell","doi":"10.1080/15412555.2026.2705831","DOIUrl":"10.1080/15412555.2026.2705831","url":null,"abstract":"<p><p>Long-term smokers with persistent dyspnoea and exercise intolerance, who are at risk for COPD, require careful clinical assessment. However, many such individuals have only minor abnormalities on spirometry, and it is not known if various additional tests of small airways dysfunction (SAD) or pulmonary microvascular deficits, offer added clinical value. In this study we wished to determine which of the available resting pulmonary function tests (e.g. airway mechanics and lung diffusing capacity for carbon monoxide, DL_CO) best uncover the physiological underpinnings of these troublesome respiratory symptoms. This tri-centre, prospective study enrolled 90 volunteers: 33 non-smoker controls, 57 symptomatic smokers, 38 of whom had Global Initiative for Obstructive Lung Disease Grade 1 COPD). Participants completed impulse oscillometry (IOS), spirometry, body plethysmography, DL_CO, single and multiple breath nitrogen washout and an incremental cycle cardiopulmonary exercise test. Smokers had more diverse physiological abnormalities, greater dyspnoea and exercise intolerance than healthy controls. Stepwise multilinear regression revealed that DL_CO was the only independent predictor of dyspnoea burden (ratio of peak dyspnoea score to peak oxygen uptake (<i>V̇</i>O_2peak)), lower <i>V̇</i>O_2peak, higher ventilatory equivalent for carbon dioxide (<i>V̇</i>_E/<i>V̇</i>CO₂ nadir) and dynamic inspiratory mechanical constraints (higher tidal volume to inspiratory capacity ratio), after accounting for age, sex, height, and smoking history. In symptomatic smokers, reduced DL_CO, contributed more to the variance in exertional dyspnoea and exercise intolerance than all airway mechanical measurements. This attests to the added value of DL_CO for clinicians assessing the nature and extent of smoking-related lung injury in individuals with only minor airway obstruction.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2705831"},"PeriodicalIF":2.8,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Relationship Between Chronic Obstructive Pulmonary Disease and Respiratory Tuberculosis Susceptibility: A Two-Sample Bayesian Weighted Mendelian Randomization Study.","authors":"Abulikemu Aili, Yan Zhang, Xiaomin Wang, Baofeng Wen, Junan Wang, Mingqin Cao","doi":"10.1080/15412555.2026.2706661","DOIUrl":"https://doi.org/10.1080/15412555.2026.2706661","url":null,"abstract":"<p><p>The causal relationship between chronic obstructive pulmonary disease (COPD) and respiratory tuberculosis (TB) remains unclear due to limited evidence from prospective studies. Therefore, this study aimed to assess the causal relationship between COPD and respiratory TB using a two-sample Bayesian weighted Mendelian randomization (BWMR) study. The genetic instrumental variants (IVs) for COPD and respiratory TB were obtained from the IEU Open GWAS project in 2021. The inverse variance weighted (IVW) method was used as the main statistical analysis method, and the results supplemented with weighted median and BWMR methods. Pleiotropy was tested using the MR-PRESSO global test and MR-Egger regression. Heterogeneity was analyzed using Cochran's Q statistics. The robustness of the results was tested using the leave-one-out sensitivity analysis method. In our two-sample BWMR analysis, we found that patients with COPD had a higher risk of respiratory TB based on IVW (OR = 1.259, 95% CI: 1.011-1.568; <i>p</i> = 0.040), weighted median (OR = 1.287, 95% CI: 0.981-1.688; <i>p</i> = 0 0.069), and BWMR (OR = 1.240, 95% CI: 1.013-1.518; <i>p</i> = 0.037). Reverse BWMR analysis showed that respiratory TB has no causal effect on COPD. We found no significant pleiotropy or heterogeneity in all selected IVs. The results were stable when removing the SNPs individually. This two-sample BWMR study provided strong evidence that individuals with COPD are at a higher risk of respiratory TB at the genetic level, while respiratory TB has no causal effect on COPD.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2706661"},"PeriodicalIF":2.8,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Real-World Prospective Observational Study to Describe the Safety Profile and Clinical Outcomes of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) In Chinese Patients with Chronic Obstructive Pulmonary Disease (COPD).","authors":"Yongchang Sun, Yunfeng Chen, Xiuwei Zhang, Ruibin Guo, Luqian Zhou, Jiaxi Feng, Xiaomin Xiong, Weiguo Xu, Guoping Li, Jing Zhang","doi":"10.1080/15412555.2026.2705830","DOIUrl":"10.1080/15412555.2026.2705830","url":null,"abstract":"<p><strong>Objectives: </strong>This observational, multicenter, prospective, single-arm study (NCT04536402) aimed to describe the safety profile and clinical outcomes of Budesonide/Glycopyrrolate/Formoterol Fumarate metered dose inhaler (BGF MDI) for Chinese patients with COPD in clinical practice.</p><p><strong>Methods: </strong>COPD patients who had been prescribed and had planned to take at least one inhalation of BGF MDI were followed-up for 12 weeks at 4-week intervals. The primary endpoints were incidences of adverse events (AEs) and serious adverse events (SAEs). Secondary endpoints included changes from baseline in COPD Assessment Test (CAT) score and St George's Respiratory Questionnaire (SGRQ) score and patient global impression of change (PGIC) scale at week 4. Patients were also stratified into subgroups according to the asthma history, exacerbation history, and baseline treatment and assessed.</p><p><strong>Results: </strong>Of the enrolled 3,317 patients, 2,137 completed and 1,180 discontinued the study. No unexpected safety signals were observed; most AEs were mild (13.2%) or moderate (7.2%). SAEs occurred in 4.9% of patients. BGF MDI was associated with decreased CAT and SGRQ total scores (mean [SD] changes from baseline: -6.7 [7.27], -14.5 [18.19]) and increased FEV₁ (189 mL, <i>n</i> = 241) at week 12. Similar trend of improvement was also observed in the subgroups. At week 4, 84.8% rated overall PGIC status as \"improved,\" and 87.6% were satisfied with the MDI device.</p><p><strong>Conclusion: </strong>In real-world practice, BGF MDI demonstrated good tolerability consistent with previous RCTs, and associated with a trend toward improvement in patients' symptoms, quality of life, and lung function, regardless of asthma history, exacerbation history, or baseline treatment.</p><p><strong>Trial registration: </strong>NCT04536402 (ClinicalTrials.gov), registered on 28 August 2020.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2705830"},"PeriodicalIF":2.8,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Ferroptosis-Related Signature Genes and Immune Landscape in Acute Exacerbation of Chronic Obstructive Pulmonary Disease\".","authors":"Tai Yayum, Mousumi Saha, Shanvi Priya, Subhasish Chatterjee","doi":"10.1080/15412555.2026.2638843","DOIUrl":"https://doi.org/10.1080/15412555.2026.2638843","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2638843"},"PeriodicalIF":2.8,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptom Improvement with BDP/FF/G Fixed Triple Inhalation Powder in Moderate to Severe COPD Patients Uncontrolled with Dual Therapies: A Non-Interventional, Open-Label, Single-Arm, Prospective Study (RESPONSE Slovenia).","authors":"Matevž Harlander, Tjaša Šubic, Renato Eržen, Arjana Maček Cafuta, Anton Lopert, Alojz Horvat, Dušan Božič, Albert Klobučar, Zoran Krstić, Nataša Todorović, Nina Sobotkiewicz, Simona Kirbiš, Ana Novaković, Nikša Šegota, Branislav Červenjak, Jasmina Panjan Avramovič, Kata Paun, Lucija Gabršček Parežnik","doi":"10.1080/15412555.2026.2681198","DOIUrl":"10.1080/15412555.2026.2681198","url":null,"abstract":"<p><p>People living with COPD are frequently inadequately treated due to underdiagnosis or misdiagnosis. The aim of this study was to evaluate the real-world performance of the beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed triple combination formulated in a dry powder inhaler (DPI) in improving symptoms, lung function, and adherence in moderate to severe COPD patients uncontrolled on dual therapies. We conducted a non-interventional, open-label, single-arm, multicenter, prospective study across 19 outpatient centers in Slovenia. The primary objective was to measure symptom improvement with the COPD Assessment Tool (CAT). A total of 359 patients with moderate to severe COPD (97% classified as GOLD E, frequent exacerbators) were followed for 24 weeks. There was a significant 6-point reduction in the CAT score after switching from dual therapies to BDP/FF/G inhalation powder (95% CI: -7.0 to -5.5; <i>p</i> < 0.0001). FEV₁ increased by 110 mL (95% CI: 90-130; <i>p</i> < 0.0001) and FVC by 95 mL (95% CI: 65-120; <i>p</i> < 0.0001), reaching a statistically significant improvement of 2.5 percentage points in the FEV₁/FVC quotient. The net improvement in dyspnea severity was 50.9% (95% CI 44.7%-57.2%), as assessed using the modified Medical Research Council (mMRC) Scale. Treatment adherence improved significantly after 6 months of triple therapy. In our cohort, switching uncontrolled moderate-to-severe COPD patients from dual therapy to BDP/FF/G fixed triple inhalation powder led to significant improvements in symptoms, lung function, dyspnea, sleep quality, and treatment adherence.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2681198"},"PeriodicalIF":2.8,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory-Endocrinology Multidisciplinary Co-Management Pathway in Hospitalized Patients with ECOPD and Diabetes: A Randomized Controlled Trial.","authors":"Bei-Bei Zhang, Cai-Feng Li, Hai-Yan Fan","doi":"10.1080/15412555.2026.2672702","DOIUrl":"10.1080/15412555.2026.2672702","url":null,"abstract":"<p><p>Exacerbation of chronic obstructive pulmonary disease (ECOPD) frequently coexists with diabetes mellitus, creating competing priorities for respiratory stabilization and safe inpatient glycemic control. Evidence for an integrated, respiratory-endocrinology co-management pathway in this population remains limited. A total of 162 inpatients hospitalized with ECOPD and comorbid diabetes between January 1 and December 31, 2025 were randomly allocated to a respiratory-endocrinology multidisciplinary co-management pathway or usual care. The intervention comprised an ECOPD care bundle, protocolized glycemic management, pulmonary rehabilitation, and a structured discharge transition package. Primary outcomes were chronic airways assessment test (CAAT) and patient-day hyperglycemia/hypoglycemia. Secondary outcomes included length of stay, 30-day readmission, functional capacity assessed by the 1-min sit-to-stand (1-min STS) test (at discharge and 30 days), patient satisfaction (CSQ-8; at discharge and 30 days), and care-transition quality measured by the Care Transitions Measure-3 (CTM-3; at 7 and 30 days). Compared with usual care, co-management yielded clinically meaningful improvements in CAAT at discharge and at 30 days. Co-management reduced hyperglycemic patient-days (rate ratio 0.799) without an increase in mild, moderate or severe hypoglycemia. The intervention group also had a shorter length of stay, a lower 30-day readmission rate, higher CSQ-8 scores, higher CTM-3 scores, and greater 1-min sit-to-stand performance at discharge and 30 days. Findings were consistent in sensitivity analyses restricted to systemic corticosteroid recipients. A structured respiratory-endocrinology multidisciplinary co-management pathway improved ECOPD-related health status and inpatient glycemic safety while enhancing functional recovery, patient experience, and short-term utilization outcomes in hospitalized patients with ECOPD and diabetes.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2672702"},"PeriodicalIF":2.8,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AVAPS Versus BiPAP in Acute Hypercapnic Respiratory Failure: A Systematic Review and Meta-Analysis.","authors":"Bryan Gregory, Charles Ezenwanne, Ahmed Dawood Al Mahrizi, Harman Gill, Fatima Mossolem, Song Ang Peng, Carlos Valladares, Wajahat Khan, Katrina Villegas","doi":"10.1080/15412555.2026.2671706","DOIUrl":"10.1080/15412555.2026.2671706","url":null,"abstract":"<p><p>Noninvasive ventilation (NIV) is increasingly used in acute and chronic hypercapnic respiratory failure (HRF), with BiPAP traditionally considered the standard mode. Average volume assured pressure support (AVAPS) adjusts inspiratory pressure to maintain target tidal volume, potentially improving CO₂ clearance. Its comparative clinical effectiveness remains uncertain. We conducted a systematic review and meta-analysis per PRISMA 2020 guidelines (PROSPERO ID: CD1031775), searching MEDLINE, EMBASE, Cochrane CENTRAL, Scopus, Web of Science, and gray literature through March 2025. Eligible studies were RCTs or comparative cohort studies in adults (≥18 years) with acute HRF or equivalent emergency indications, directly comparing AVAPS and BiPAP. Primary outcomes were endotracheal intubation and short-term mortality; secondary outcomes included arterial blood gases (pH, pO₂, pCO₂) and hospital length of stay (LOS). Random-effects meta-analysis (Hartung-Knapp) and one-way ANOVA of arm-level means were applied, with evidence graded using GRADE. Eleven studies met inclusion criteria (<i>n</i> = 280 for intubation, <i>n</i> = 300 for mortality). AVAPS significantly reduced intubation risk compared with BiPAP (RR 0.43, 95% CI 0.23-0.79; <i>p</i> = 0.027; I² = 0%), corresponding to a 57% relative and 4.7% absolute risk reduction (NNT ≈ 21). No significant difference in short-term mortality was observed (RR 0.87, 95% CI 0.38-2.00; <i>p</i> = 0.62; I² = 31.8%), though exploratory NNT favored AVAPS (47). Physiological outcomes and LOS were similar between groups (all <i>p</i> > 0.63). In adults with acute HRF, AVAPS lowers intubation rates compared with BiPAP, without clear short-term survival benefit. Physiological outcomes and LOS appear equivalent. AVAPS may be preferred for selected patients, though larger, high-quality RCTs are needed to confirm the mortality effects.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2671706"},"PeriodicalIF":2.1,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional, and National Burden of COPD Attributable to Secondhand Smoke from 1990 to 2021: Findings from the Global Burden of Disease Study 2021.","authors":"Hang Su, Yuning Huang, Yanmei Lin, Wuping Bao, Yuchen Lin, Min Zhang","doi":"10.1080/15412555.2026.2657479","DOIUrl":"https://doi.org/10.1080/15412555.2026.2657479","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a leading global cause of death and disability, with a disproportionate burden in low- and middle-income countries. Secondhand smoke (SHS) contributes substantially to the COPD burden through toxic mechanisms. Current evidence on the COPD burden attributable to SHS remains limited.</p><p><strong>Methods: </strong>Disability-adjusted life years (DALYs) were estimated using data from the Global Burden of Disease (GBD) 2021 study (1990-2021) by age, sex, and Socio-Demographic Index (SDI). Temporal trends were assessed using estimated annual percentage change, health inequality analyses were conducted across SDI groups, and projections were performed with Bayesian age-period-cohort models.</p><p><strong>Results: </strong>In 2021, 7.09% of global COPD DALYs were attributable to SHS, highest in Oceania and South Asia, lowest in Latin America and high-income Asia. From 1990 to 2021, the age-standardized DALY rate of COPD attributable to SHS declined in Europe, North America, Sub-Saharan Africa, and the Middle East, with pronounced reductions in both sexes. In Asia, Latin America, and the Caribbean, declines slowed, projected to rise after 2021. DALYs showed age- and sex-specific patterns, males higher in high- and low-SDI regions, females in others, peak burden at 70-74, varying across SDI levels. DALYs were negatively associated with SDI, with regional variations and persistent health inequalities, increasingly concentrated in higher-SDI regions.</p><p><strong>Conclusion: </strong>The global COPD-SHS burden varies by socioeconomic status, geography, age, and sex. Despite overall declines, it remains high in Asia and North Africa, disproportionately affecting older adults and economically underdeveloped regions, highlighting the need for targeted interventions.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"23 1","pages":"2657479"},"PeriodicalIF":2.8,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}